Methods for neuroprotection

• US 5,554,601 A
• Filed: 10/04/1994
• Issued: 09/10/1996
• Est. Priority Date: 11/05/1993
• Status: Expired due to Term

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida (State University System of Florida)
• Inventors: Singh, Meharvan, Bishop, Jean, Simpkins, James W.
• Primary Examiner(s): Weddington, Kevin E.
• Application Number:
  US08/318,042
• Time in Patent Office: 707 Days
• Field of Search: 514/171, 514/170, 514/169, 514/179, 514/181, 514/182
• US Class Current: 514/182
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

A method is provided for conferring neuroprotection on a population of cells using estrogen compounds that have insubstantial sex activity and furthermore, a method is provided that utilizes estrogen compounds in the absence of testosterone for treating neurodegenerative diseases including Alzheimer'"'"'s disease so as to retard the adverse effects of these disorders, Examples of estrogen compounds that have insubstantial sex activity includes alpha isomers of estrogen compounds such as 17α estradiol.

Claims

1. A method of conferring neuroprotection on a population of cells in a subject, comprising:

(i) providing an estrogen compound; and

(ii) administering the compound in the absence of testosterone, in an effective dose, to the population of cells so as to confer neuroprotection.

2. A method according to claim 1, wherein the estrogen compound has a general structure:

##STR2## a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein the R2-group on C17 in an α

isomeric position.

3. A method according to claim 2, further comprising the R2 group on C17 being an hydroxyl in the α

isomeric position.

4. A method according to claim 2, wherein the R1 group and the R2 group are independently selected from the group consisting of hydrogen, hydroxyl, oxygen, methyl, methyl ester, acetate, ethyl ether, 3,3 dimethyl ketal, 17,17 dimethyl ketal, ethynyl-α

, benzoate, benzyl ether, glucuronide, valerate, cyclopentylpropionate, propionate, hemisuccinate, palmitate, enanthate, stearate, cypionate.

5. A method according to claim 2, wherein the R1 group and the R2 group are independently selected from the group consisting of sodium glucuronide, sulfite sodium salt, sodium phosphate, and trimethyl ammonium salt.

6. A method according to claim 1, wherein the cell population includes neuronal cells.

7. A method according to claim 6, wherein the neuronal cells include cholinergic neurons.

8. A method according to claim 6, wherein the neuronal cells include hippocampal cells.

9. A method according to claim 6, wherein the neuronal cells include cortex cells.

10. A method according to claim 9, wherein the neuronal cells include glial cells.

11. A method according to claim 1, wherein the step of administering an α

estrogen compound to a nerve cell population is preceded by the step of administering the compound to a site within a subject so as to decrease loss of neuronal activity in the subject.

12. A method according to claim 11, wherein the site of loss of neuron activity in the subject is selected from the group consisting of hippocampus, cortex and basal forebrain.

13. A method according to claim 11, wherein the loss of neuronal activity is associated with a chronic degenerative disorder.

14. A method according to claim 11, wherein the loss of neuronal activity is associated with an acute degenerative disorder.

15. A method according to claim 11, wherein the loss of neuronal activity is associated with trauma at the site.

16. A method according to claim 11, wherein the loss of neuronal activity is associated with overstimulation of the excitatory amino acid receptors on neurons.

17. A method according to claim 11, further comprising administering the estrogen compound by one of the group of routes consisting of oral, buccal, intramuscular, transdermal, intravenous and subcutaneous.

18. A method according to claim 17, further comprising administering the estrogen compound in a controlled release vehicle.

19. A method according to claim 17, further comprising administering the estrogen compound orally.

20. A method according to claim 17, further comprising administering the estrogen compound subcutaneously.

21. A method according to claim 11, further comprising the step of causing a reversal of loss of memory and loss of learning function.

22. A method according to claim 4, wherein R1 is a hydroxyl group and R2 is selected from the group consisting of hydrogen, hydroxyl, oxygen, methyl, methyl ester, acetate, ethyl ether, 3,3 dimethyl ketal, 17,17 dimethyl ketal, ethynyl-α

, benzoate, benzyl ether, glucuronide, valerate, cyclopentylpropionate, propionate, hemisuccinate, palmitate, enanthate, stearate, cypionate.

29. A method according to claim 20, wherein the estrogen compound has the following structure:

##STR3## a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein the R2 -group on C17 is a hydroxyl group in an α

isomeric position and the R1 group on C3 is a hydroxyl group in a β

isomeric position.

23. A method of treating a neurodegenerative disorder in a subject, comprising;

(i) providing an effective dose of an estrogen compound, in a pharmaceutical formulation; and

(ii) administering the formulation in the absence of testosterone, to the subject so as to retard adverse effects of the disorder.

24. A method according to claim 23, wherein the estrogen compound is α

-estradiol.

26. A method according to claim 23, wherein the neurodegenerative disorder is Alzheimer'"'"'s disease and the effective dose of the estrogen compound provides protection of a population of nerve cells from progressive cell damage leading to cell death otherwise occurring without any intervention.

25. A method of treating a neurodegenerative disorder in a male subject, comprising:

(i) providing an effective dose of an estrogen compound in a pharmaceutical formulation; and

(ii) administering the formulation to the subject so as to retard adverse effects of the disorder.

27. A method according to claim 25, wherein the neurodegenerative disorder is Alzheimer'"'"'s disease and the effective dose of estrogen compound provides protection of a population of nerve cells from progressive cell damage leading to cell death otherwise occurring without any intervention.

28. A method of conferring neuroprotection on a population of cells in a subject, comprising:

(i) providing an estrogen compound having insubstantial sex-related activity, in a pharmaceutical formulation; and

(ii) administering the formulation in an effective dose to the population of cells to confer neuroprotection.